Forced expression of cyclin-dependent kinase 6 confers resistance of Pro-B acute lymphocytic leukemia to gleevec treatment

Molecular and Cellular Biology

Volumn 31, Issue 13, 2011, Pages 2566-2576

  Kuo, Tracy C ^a,b   Chavarria Smith, Joseph E ^a   Huang, Dan ^a   Schlissel, Mark S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN DEPENDENT KINASE 6; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR E2A;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; DRUG RESISTANCE, NEOPLASM; GENE LIBRARY; HUMANS; PIPERAZINES; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; TRANSCRIPTION, GENETIC;

ABELSON MURINE LEUKEMIA VIRUS; MURINAE;

EID: 79959466807     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01349-10     Document Type: Article

References (46)

1. Aceves-Luquero, C. I., et al. 2009. ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS One 4:e6124.
2. Agirre, X., et al. 2009. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69:4443-4453.
3. Amin, R. H., and M. S. Schlissel. 2008. Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat. Immunol. 9:613-622.
4. Chen, Y. Y., L. C. Wang, M. S. Huang, and N. Rosenberg. 1994. An active v-abl protein tyrosine kinase blocks immunoglobulin light-chain gene rearrangement. Genes Dev. 8:688-697.
5. Choe, K. S., O. Ujhelly, S. N. Wontakal, and A. I. Skoultchi. 2010. PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells. J. Biol. Chem. 285:3044-3052.
6. Deed, R. W., E. Hara, G. T. Atherton, G. Peters, and J. D. Norton. 1997. Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol. Cell. Biol. 17:6815-6821.
7. Ericson, K. K., D. Krull, P. Slomiany, and M. J. Grossel. 2003. Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes. Mol. Cancer Res. 1:654-664.
8. Feldhahn, N., et al. 2007. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J. Exp. Med. 204:1157-1166.
9. Fry, D. W., et al. 2004. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3:1427-1438.
10. Greenbaum, S., and Y. Zhuang. 2002. Identification of E2A target genes in B lymphocyte development by using a gene tagging-based chromatin immunoprecipitation system. Proc. Natl. Acad. Sci. U. S. A. 99:15030-15035.
11. Grossel, M. J., G. L. Baker, and P. W. Hinds. 1999. cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J. Biol. Chem. 274:29960-29967.
12. Grossel, M. J., and P. W. Hinds. 2006. Beyond the cell cycle: a new role for Cdk6 in differentiation. J. Cell Biochem. 97:485-493.
13. Grosso, S., et al. 2009. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol. Cancer Ther. 8:1924-1933.
14. Hara, E., M. Hall, and G. Peters. 1997. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. EMBO J. 16: 332-342.
15. Kee, B. L. 2009. E and ID proteins branch out. Nat. Rev. Immunol. 9:175-184.
16. Kharas, M. G., and D. A. Fruman. 2005. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 65:2047-2053.
17. Klug, C. A., et al. 1994. The v-abl tyrosine kinase negatively regulates NFkappa B/Rel factors and blocks kappa gene transcription in pre-B lymphocytes. Genes Dev. 8:678-687.
18. Koleske, A. J., et al. 1998. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21:1259-1272.
19. Koyasu, S. 2003. The role of PI3K in immune cells. Nat. Immunol. 4:313-319.
20. Lazorchak, A. S., M. S. Schlissel, and Y. Zhuang. 2006. E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells. Mol. Cell. Biol. 26:810-821.
21. Lee, T. I., S. E. Johnstone, and R. A. Young. 2006. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 1:729-748.
22. Lenardo, M., J. W. Pierce, and D. Baltimore. 1987. Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. Science 236:1573-1577.
23. Mahony, D., D. A. Parry, and E. Lees. 1998. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 16:603-611.
24. Malumbres, M., and M. Barbacid. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9:153-166.
25. Mandal, M., et al. 2009. Ras orchestrates exit from the cell cycle and lightchain recombination during early B cell development. Nat. Immunol. 10: 1110-1117.
26. Matushansky, I., F. Radparvar, and A. I. Skoultchi. 2003. CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells. Oncogene 22:4143-4149.
27. Matushansky, I., F. Radparvar, and A. I. Skoultchi. 2000. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc. Natl. Acad. Sci. U. S. A. 97:14317-14322.
28. Melo, J. V., and C. Chuah. 2007. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 249:121-132.
29. Muljo, S. A., and M. S. Schlissel. 2003. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines. Nat. Immunol. 4:31-37.
30. Munoz-Alonso, M. J., et al. 2005. p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J. Biol. Chem. 280:18120-18129.
31. Murre, C. 2005. Helix-loop-helix proteins and lymphocyte development. Nat. Immunol. 6:1079-1086.
32. Radfar, A., I. Unnikrishnan, H. W. Lee, R. A. DePinho, and N. Rosenberg. 1998. p19Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. U. S. A. 95:13194-13199.
33. Rosenberg, N. 1994. Abl-mediated transformation, immunoglobulin gene rearrangements and arrest of B lymphocyte differentiation. Semin. Cancer Biol. 5:95-102.
34. Rosenberg, N., and O. N. Witte. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 35:39-81.
35. Sachs, Z., N. E. Sharpless, R. A. DePinho, and N. Rosenberg. 2004. p16Ink4a interferes with Abelson virus transformation by enhancing apoptosis. J. Virol. 78:3304-3311.
36. Schwartz, R., I. Engel, M. Fallahi-Sichani, H. T. Petrie, and C. Murre. 2006. Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc. Natl. Acad. Sci. U. S. A. 103:9976-9981.
37. Schwartzberg, P. L., et al. 1991. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 65:1165-1175.
38. Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705-716.
39. Shah, N. P., et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
40. Skorski, T., et al. 1996. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. U. S. A. 93:13137-13142.
41. Thome, K. C., A. Radfar, and N. Rosenberg. 1997. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. J. Virol. 71:8149-8156.
42. Tybulewicz, V. L., C. E. Crawford, P. K. Jackson, R. T. Bronson, and R. C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163.
43. Weinberger, J., D. Baltimore, and P. A. Sharp. 1986. Distinct factors bind to apparently homologous sequences in the immunoglobulin heavy-chain enhancer. Nature 322:846-848.
44. Wong, S., and O. N. Witte. 2004. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22:247-306.
45. Zhao, F., A. Vilardi, R. J. Neely, and J. K. Choi. 2001. Promotion of cell cycle progression by basic helix-loop-helix E2A. Mol. Cell. Biol. 21:6346-6357.
46. Zou, X., S. Rudchenko, K. Wong, and K. Calame. 1997. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclindependent kinases. Genes Dev. 11:654-662.